Source comparison
TB-500 Research Hepatic Considerations: Safety Comparison
Hepatotoxicity Signal None detected at ≤10mg weekly × 12 weeks None at standard doses N/A Both peptides show favorable hepatic safety profiles in current literature Transaminase Effect ALT/AST within normal range in preclinical models Similar. No elevation Bas
This comparison does not assign a generated winner or score.
- Hepatotoxicity Signal
- None detected at ≤10mg weekly × 12 weeks
- None at standard doses
- N/A
- Both peptides show favorable hepatic safety profiles in current literature
- Transaminase Effect
- ALT/AST within normal range in preclinical models
- Similar. No elevation
- Baseline reference
- Monitor if combining with hepatotoxic compounds or exceeding 12-week protocols
- Fibrosis Impact
- 47–52% reduction in collagen deposition (animal models)
- Limited hepatic-specific data
- No effect
- TB-500 demonstrates measurable antifibrotic activity; BPC-157 research focuses on GI/musculoskeletal applications
- Inflammatory Markers
- TNF-α ↓38%, IL-6 ↓44% in liver tissue
- Broad anti-inflammatory effects
- No reduction
- TB-500's NF-κB inhibition produces quantifiable hepatic inflammation suppression
- Clearance Pathway
- Enzymatic degradation (peptidases), t½ 2.5–3.5 hours
- Enzymatic, similar kinetics
- Rapid clearance minimizes accumulation risk but requires consistent dosing
- Long-Term Data
- Limited human hepatic outcome data beyond 12 weeks
- Similarly limited
- Both require extended monitoring protocols to establish chronic safety profiles